April 18, 2017 / 1:18 AM / 6 months ago

BRIEF-FDA grants Genentech’s tecentriq accelerated approval

April 17 (Reuters) - Roche Holding Ag:

* FDA grants Genentech’s tecentriq (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer

* Genentech - “it is not known if tecentriq is safe and effective in children” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below